Home »

Akers Biosciences Announces Q2 2017 Earnings

Total Revenues for Q2 Up 25%

Akers Biosciences Announces Board Changes

Experienced directors with medical device and financial backgrounds to steer the Company through next phase of growth

Akers Biosciences Announces Second Quarter Trading Update

Second Quarter Revenues Up 25% over Q2 2016

Akers Biosciences Announces a $2 Million Private Placement

THOROFARE, NJ — (Marketwired) — 03/30/17 — Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, announces a private placement to raise approximately $2 million. Akers Bio will use the proceeds from the transaction as growth capital and for general corporate purposes.Akers Bio will issue 1,448,400 shares at a price of $1.40 per share, resulting in gross proceeds to the Company of $2,027,7

Akers Biosciences Reports Preliminary Unaudited Earnings Highlights for Fiscal Year 2016

Sales of Flagship Rapid HIT Test +85% over 2015

Akers Biosciences Announces Closing of Public Offering

THOROFARE, NJ — (Marketwired) — 01/13/17 — Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, today announces the closing of its previously announced underwritten public offering of 1,667,000 shares of common stock at a public offering price of $1.20 per share together with the issuance of 833,500 five-year warrants to purchase common stock with an exercise price of $1.50. In addition, t

Akers Biosciences Announces Pricing of Public Offering of 1,667,000 Shares and 833,500 Warrants

THOROFARE, NJ — (Marketwired) — 01/09/17 — Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, today announces the entry into an agreement relating to the sale of 1,667,000 shares of common stock at a public offering price of $1.20 per share together with the issuance of 833,500 five-year warrants to purchase common stock with an exercise price of $1.50. The gross proceeds from the offe

Akers Biosciences Signs 3-year Agreement with GNYHA Services for Heparin PF4 Rapid Test

THOROFARE, NJ — (Marketwired) — 12/22/16 — Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, reported on December 19, 2016 that the Company has signed a three-year agreement with the Greater New York Hospital Association (GNYHA) to introduce the Company–s flagship rapid tests for heparin-induced thrombocytopenia across GNYHA–s network of over 300 member hospitals and health systems.

Analytics

© 2020 88Finance. All Rights Reserved. Log in - Copyright by LayerMedia


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de